Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
Source: https://www.cnbc.com/2024/04/25/bristol ... -2024.html
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
